8-K: ENDRA Life Sciences Secures $1.75M ATM Equity Facility

ENDRA Life Sciences Inc. has entered into an At-The-Market Issuance Sales Agreement to potentially raise up to $1.75 million through common stock sales.

Summary

• ENDRA Life Sciences Inc. (the Company) entered into an At-The-Market Issuance Sales Agreement (ATM Agreement) with Lucid Capital Markets, LLC on October 29, 2025.
• The agreement allows the Company to offer and sell shares of its common stock for aggregate gross proceeds of up to $1,750,000.
• Sales will be made through Lucid Capital Markets, LLC as the sales agent, primarily in at-the-market equity offerings on or through the Nasdaq Capital Market.
• The Company has no obligation to sell any shares and can suspend or terminate offers at any time.
• Lucid Capital Markets, LLC will receive a commission of up to 3.0% of the aggregate gross proceeds from any shares sold.
• The ATM Agreement will terminate upon the earlier of the sale of all shares, termination by either party, or the three-year anniversary of the agreement date.

Sentiment

Score: 6

Explanation: The filing indicates a proactive step to secure flexible funding, which is positive for liquidity management. However, it also introduces potential dilution for existing shareholders, and the relatively small amount suggests ongoing capital needs rather than a significant breakthrough.

Positives

• Provides access to capital of up to $1,750,000, enhancing financial flexibility.
• Allows for opportunistic fundraising at prevailing market prices, minimizing upfront costs compared to traditional underwritten offerings.
• The Company retains control, with no obligation to sell shares and the ability to suspend or terminate the agreement.

Negatives

• Potential for shareholder dilution as new common stock shares are issued.
• Commission of up to 3.0% of gross proceeds will reduce net funds received by the Company.
• The timing and pricing of sales are subject to market conditions, which could impact the actual proceeds realized.

Risks

• Dilution: The issuance of new common stock shares could dilute the ownership interest of existing shareholders.
• Market Price Volatility: The actual proceeds from the ATM facility depend on the market price of the common stock at the time of sale, which can be volatile.
• Termination Risk: The ATM Agreement can be terminated by either party, or automatically, which could limit the Company's access to this funding source.
• Regulatory Compliance: Ongoing compliance with SEC and Nasdaq rules is required for the ATM program.

Future Outlook

The ATM Agreement provides ENDRA Life Sciences Inc. with a flexible and efficient mechanism to access capital over the next three years, supporting its ongoing operations and strategic initiatives without committing to a fixed offering size or timing.

Management Comments

• ENDRA Life Sciences Inc. confirms its agreement with Lucid Capital Markets, LLC as agent.
• The Company has no obligation to sell any of the Shares, and may at any time suspend offers under the Agreement or terminate the Agreement.

Industry Context

At-the-market (ATM) offerings are a common financing tool for smaller public companies, particularly in the life sciences sector, to raise capital incrementally and opportunistically. This method allows companies to tap into market liquidity as needed, often to fund research and development, clinical trials, or general corporate purposes, without the significant upfront costs and market disruption associated with traditional underwritten offerings.

Comparison to Industry Standards

• ATM offerings are a standard practice for micro-cap and small-cap companies, especially in the biotech and medical device industries, to manage cash burn and fund operations.
• The commission rate of up to 3.0% is within the typical range for ATM facilities, which can vary from 1% to 5% depending on the company size, liquidity, and agent.
• The maximum raise of $1.75 million is relatively small, suggesting it's intended for short-term operational needs or specific, smaller projects rather than a major strategic shift, which is common for companies at ENDRA's stage.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution of existing shareholdings due to the issuance of new common stock.
• Company: Enhanced financial flexibility and access to capital for general corporate purposes, R&D, or other strategic initiatives.
• Creditors: Improved liquidity could indirectly strengthen the Company's ability to meet its obligations.

Next Steps

• The Company may, from time to time, offer and sell shares of its common stock through Lucid Capital Markets, LLC.
• The Company will prepare and file a prospectus supplement relating to the Placement Shares.
• The Company will continue to comply with SEC reporting requirements and maintain the effectiveness of its registration statement.

Key Dates

Keywords

ENDRA Life Sciences, NDRA, ATM Agreement, At-The-Market, Equity Offering, Capital Raise, Nasdaq, Lucid Capital Markets, Dilution, SEC Filing, Form 8-K